Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005862 · ClinicalTrials.gov registry record · Phase 1
Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT01005862 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 17 participants.
The verdict
NCT01005862, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary goal of this study is to evaluate the effect of PF-04360365 on the clearance of ABETA from the CSF (cerebrospinal fluid) in patients with mild Alzheimer's disease and healthy volunteers. Additionally, the study will assess the pharmacokinetics of PF-04360365, pharmacokinetic and pharmacodynamic relationships in plasma and CSF and the safety and tolerability of single doses of PF-04360365 administered to patients with Alzheimer's disease and healthy volunteers.
Interventions
- DRUG Placebo
- BIOLOGICAL PF-04360365
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005862
The ClinicalTrials.gov registry entry for NCT01005862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01005862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005862 about?
NCT01005862 is a clinical study titled "Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers". The primary goal of this study is to evaluate the effect of PF-04360365 on the clearance of ABETA from the CSF (cerebrospinal fluid) in patients with mild Alzheimer's disease and healthy volunteers. Additionally, the study will assess the pharmacokinetics of PF-04360365, pharmacokinetic and pharmaco...
What is the current status of trial NCT01005862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2010-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01005862?
The interventions under investigation include: Placebo (DRUG), PF-04360365 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01005862?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.